Infant Bacterial Therapeutics
Peter Rothschild is on the Board of Directors at Infant Bacterial Therapeutics. Peter is also the Chairman of the Board of Directors of BioGaia AB, TriPac AB, TwoPac Aktiebolag, TwoPac Machine AB, Looft Industries AB, CapAble AB, TwoPac Laboratories AB, MetaboGen AB, Atina Enterprises AB, Nefor Holding AB, and Voranco Holding AB. He also serves as a member of the Board of Directors of Glycom A/S and Annwall & Rothschild Investments AB.
Previously, Peter was CEO of BioGaia AB (publ), a member of the Board of Directors of Moberg Pharma AB, and the Institution of Biology and Biochemistry at Chalmers University.
Peter holds a Master of Business Administration from Stockholm School of Economics.
This person is not in the org chart
This person is not in any offices
Infant Bacterial Therapeutics
IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.